MediWound Ltd. (MDWD)
NasdaqGM · USD · Healthcare · Biotechnology
$12.07 (+0.54%) as of
Key statistics
- Market cap
- 155.76M
- Forward P/E
- -5.27
- EPS (TTM)
- -2.17
- Dividend yield
- 0.00%
- 52-week range
- 11.80 – 19.70
- Beta
- 0.09
- Revenue (TTM)
- 11.86M
- Profit margin
- -170.10%
- Analyst target
- $30.67
- Volume
- 83.89k
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Yavne, Israel
- Employees
- 121
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.